Anorexia Nervosa
Conditions
Keywords
Anorexia nervosa, Anorexia, Eating disorders
Brief summary
The purpose of this study is to determine if administration of RM-131 is effective in improving appetite and gastrointestinal symptoms leading to the recovery of patients with anorexia nervosa in the outpatient setting.
Interventions
DRUGRM-131
RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
DRUGPlacebo
Sponsors
Motus Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* DSM-IV criteria for anorexia nervosa, including weight \<85% of ideal body weight (IBW) and amenorrhea for three months; * Age 18-45 years old; * Gastrointestinal tract symptoms; * Non-hormonal method of birth control, which must be used throughout the study. Female patients unable to bear children must have this documented (i.e., tubal ligation, hysterectomy, or post-menopausal, defined as a minimum of one year since the last menstrual period and elevated FSH); * Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to baseline; * Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures, including daily SC injections and completion of a daily injection log. * Patient has a primary care physician or treatment team managing her care.
Exclusion criteria
* Use of hormone therapy (including but not limited to estrogen, progesterone) or hormonal methods of birth control (i.e., oral, implantable, or injectable) within eight weeks of screening; or Depo-Provera within six months of screening; * Pregnancy, lactation or breastfeeding, or a positive serum or urine pregnancy test, within eight weeks of screening; * History of diabetes mellitus; * History of purging behaviors greater than once monthly within the last three months; * Active substance abuse; * Use of metoclopramide, erythromycin, 5HT3 anti-emetics, or opioid medications within 2 weeks prior to baseline. \[Note: these drugs should also not be used post-baseline\]; * Hematocrit \< 30.0 %, hemoglobin \< 10.0 g/dl, potassium \< 3.0 mmol/L, fasting glucose \> 100 mg/dL, creatinine \> 1.5 mg/dL, AST or ALT \> 1.5 times the upper limit of normal, or abnormal plasma thyroid stimulating hormone (TSH) level; * Currently receiving parenteral feeding or enteral feeding, or presence of a nasogastric or other enteral tube for feeding or decompression; * History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure, small or large bowel resection; * Clinical suspicion, in the opinion of the investigator, of active or symptomatic peptic ulcer disease, cholelithiasis, colitis, celiac sprue, or inflammatory bowel disease; * Active suicidal ideation; * Beck Depression Inventory-2 score of ≥ 29; * Current inpatient hospitalization; * Allergic or intolerant of egg, milk, wheat or algae, as these are components of the GEBT test meal; * Participation in a clinical study with an investigational medication or device within the 30 days prior to dosing in the present study; * Any other reason, which in the opinion of the Investigator, including severe renal, hepatic or cardiac disease, would confound proper interpretation of the study or expose a patient to unacceptable risk.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of RM-131 on body weight | Baseline and Day 28 | Change from baseline in body weight. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of RM-131 on gastric emptying time | Baseline and Day 28 | Change from baseline in gastric half-emptying time (t1/2). |
| Effect of RM-131 on appetite | Baseline and Day 28 | Change from baseline in appetite. |
Countries
United States
Outcome results
None listed